The Orange Book (Approved Drug Products with Therapeutic Equivalence Evaluations) is an FDA compendium that lists approved prescription and over‑the‑counter drug products, application numbers (NDA/ANDA), therapeutic equivalence (TE) codes, patent and exclusivity data, and reference listed drugs (RLDs). For B.Pharm students, it is vital for understanding pharmaceutical equivalence, bioequivalence, generic substitution, patent expiry, and market entry timing. The Orange Book guides regulatory affairs, pharmacy practice, quality assurance, and formulary decisions by clarifying TE codes (e.g., AB), paragraph IV challenges, and exclusivity types (NCE, pediatric, orphan). Now let’s test your knowledge with 30 MCQs on this topic.
Q1. What is the primary purpose of the FDA Orange Book?
- To list all active pharmaceutical ingredient suppliers worldwide
- To provide approved drug products with therapeutic equivalence evaluations
- To publish clinical trial results for investigational drugs
- To list manufacturing equipment standards for pharmacies
Correct Answer: To provide approved drug products with therapeutic equivalence evaluations
Q2. Which agency publishes the Orange Book?
- World Health Organization (WHO)
- European Medicines Agency (EMA)
- U.S. Food and Drug Administration (FDA)
- Pharmacy Council of India
Correct Answer: U.S. Food and Drug Administration (FDA)
Q3. Which of the following contents is NOT typically found in the Orange Book?
- Therapeutic equivalence codes
- Patent and exclusivity listings for approved drugs
- Biologics licensed under a BLA (Purple Book content)
- Application numbers such as NDA and ANDA
Correct Answer: Biologics licensed under a BLA (Purple Book content)
Q4. What does the TE code “AB” indicate in the Orange Book?
- The product is not therapeutically equivalent
- Therapeutically equivalent to the reference product and bioequivalent
- Product is approved only for veterinary use
- Product has active patent protection and cannot be substituted
Correct Answer: Therapeutically equivalent to the reference product and bioequivalent
Q5. What does RLD stand for in the context of the Orange Book?
- Regulatory Listing Document
- Reference Listed Drug
- Restricted Launch Drug
- Required Labeling Details
Correct Answer: Reference Listed Drug
Q6. Which application types are commonly listed in the Orange Book?
- NDA and ANDA
- BLA and IND
- MAA and CEP
- CTD and eCTD only
Correct Answer: NDA and ANDA
Q7. The Orange Book is most useful for which of the following pharmacy activities?
- Designing new drug synthesis routes
- Deciding generic substitution based on TE codes
- Setting retail pharmacy hours
- Measuring drug stability under accelerated conditions
Correct Answer: Deciding generic substitution based on TE codes
Q8. Which exclusivity period is typically granted to a New Chemical Entity (NCE) in the U.S.?
- 6 months
- 3 years
- 5 years
- 10 years
Correct Answer: 5 years
Q9. What is the duration of pediatric exclusivity when granted?
- 3 months
- 6 months
- 2 years
- 5 years
Correct Answer: 6 months
Q10. Which exclusivity is typically granted for orphan drugs in the U.S.?
- 1 year
- 3 years
- 7 years
- 12 years
Correct Answer: 7 years
Q11. A Paragraph IV certification in an ANDA filing generally indicates what?
- The generic applicant agrees with the listed patents
- The applicant claims the patents are invalid or will not be infringed
- The applicant requests an extension of exclusivity
- The application is for a biologic under BLA
Correct Answer: The applicant claims the patents are invalid or will not be infringed
Q12. What is 180-day exclusivity in the Hatch-Waxman context?
- Minimum patent term for all drugs
- Exclusive marketing period granted to the first eligible ANDA filer with a successful Paragraph IV challenge
- Time allowed to file an appeal against FDA decisions
- Duration of ORPHAN exclusivity
Correct Answer: Exclusive marketing period granted to the first eligible ANDA filer with a successful Paragraph IV challenge
Q13. Which statement best describes pharmaceutical equivalence?
- Same therapeutic effect proven by clinical trials
- Same active ingredient, dosage form, strength, and route of administration
- Identical manufacturing site and process
- Same packaging materials
Correct Answer: Same active ingredient, dosage form, strength, and route of administration
Q14. Bioequivalence primarily assesses which parameter?
- Identical inactive ingredients
- Comparable rate and extent of systemic drug absorption
- Same color and shape of tablets
- Matching patent numbers
Correct Answer: Comparable rate and extent of systemic drug absorption
Q15. The Orange Book’s therapeutic equivalence evaluations are most relevant to which professional group?
- Clinical trial monitors only
- Pharmacists, regulatory professionals, and formulary committees
- Veterinarians exclusively
- Medical device manufacturers
Correct Answer: Pharmacists, regulatory professionals, and formulary committees
Q16. Which TE code indicates that a product is NOT considered therapeutically equivalent?
- AB
- AQ
- B or any code beginning with B
- AA
Correct Answer: B or any code beginning with B
Q17. Where should pharmacists look to confirm the Reference Listed Drug (RLD) for a generic application?
- Clinical trial registries
- The FDA Orange Book
- Local pharmacy formularies only
- Manufacturing batch records
Correct Answer: The FDA Orange Book
Q18. The Orange Book lists patent information submitted by whom?
- Generic drug manufacturers exclusively
- FDA inspectors during site audits
- New Drug Application (NDA) holders (brand sponsors)
- State pharmacy boards
Correct Answer: New Drug Application (NDA) holders (brand sponsors)
Q19. If a product is listed with an “AB” rating, what is the typical implication for substitution at the pharmacy level?
- It cannot be substituted under any circumstances
- It is generally considered substitutable for the RLD where state law allows
- Substitution is prohibited until patent expiry
- It requires a new clinical trial before substitution
Correct Answer: It is generally considered substitutable for the RLD where state law allows
Q20. Which of the following is a limitation of the Orange Book?
- It includes biologics approved under BLAs
- It guarantees interchangeability for all listed generics
- It relies on patents listed by NDA holders and may not reflect unlisted or disputed patents
- It contains manufacturing validation reports
Correct Answer: It relies on patents listed by NDA holders and may not reflect unlisted or disputed patents
Q21. What is the Purple Book used for, in contrast to the Orange Book?
- Listing medical devices and equipment
- Listing biologic products, biosimilars, and interchangeability determinations
- Listing over‑the‑counter herbal supplements
- Listing veterinary drug approvals
Correct Answer: Listing biologic products, biosimilars, and interchangeability determinations
Q22. Which regulatory concept explains why an ANDA may be approved without new clinical trials?
- Pharmaceutical exclusivity
- Bioequivalence demonstrating comparable pharmacokinetics to the RLD
- Pediatric study requirements
- Orphan drug status
Correct Answer: Bioequivalence demonstrating comparable pharmacokinetics to the RLD
Q23. How often is the Orange Book updated online by the FDA?
- Never; it is static once published
- Annually only
- Periodically and as new approvals, patents, or exclusivity actions occur
- Only upon congressional request
Correct Answer: Periodically and as new approvals, patents, or exclusivity actions occur
Q24. Which entry in the Orange Book helps determine the reference for bioequivalence studies?
- Manufacturing site address
- Reference Listed Drug (RLD) designation
- Label color code
- Pharmacopoeial monograph number
Correct Answer: Reference Listed Drug (RLD) designation
Q25. What role does the Orange Book play in regulatory strategy for generic manufacturers?
- Helps identify RLDs, patents, exclusivity constraints, and TE expectations for product development and timing
- Provides clinical protocols for new drug trials
- Lists contract research organizations for outsourcing
- Sets international pricing guidelines
Correct Answer: Helps identify RLDs, patents, exclusivity constraints, and TE expectations for product development and timing
Q26. If an NDA holder requests removal of a patent from the Orange Book, what does the FDA typically require?
- Automatic removal without review
- Documentation and justification to support the removal request
- Payment of a fee to the FDA for removal
- Approval from state boards of pharmacy
Correct Answer: Documentation and justification to support the removal request
Q27. Which of the following is TRUE regarding therapeutic equivalence evaluations in the Orange Book?
- They replace clinical judgment and physician prescribing decisions
- They are FDA evaluations indicating whether a generic is expected to be therapeutically equivalent to the RLD
- They certify manufacturing quality at the production site
- They guarantee identical efficacy in special populations without further evidence
Correct Answer: They are FDA evaluations indicating whether a generic is expected to be therapeutically equivalent to the RLD
Q28. Which exclusivity protects new clinical investigations such as new formulations or new indications?
- 5‑year NCE exclusivity
- 3‑year exclusivity for certain new clinical investigations
- 6‑month pediatric exclusivity
- 180‑day ANDA exclusivity
Correct Answer: 3‑year exclusivity for certain new clinical investigations
Q29. A B.Pharm student researching generic entry timing should analyze which Orange Book fields?
- Application number, TE code, patent numbers and expiration, and listed exclusivities
- Tablet color and imprint only
- Manufacturer’s profit margins
- Library references cited in approval documents
Correct Answer: Application number, TE code, patent numbers and expiration, and listed exclusivities
Q30. Which action by a generic applicant can trigger a patent infringement lawsuit by the NDA holder often referenced in Orange Book strategy?
- Submitting a Paragraph IV certification in an ANDA
- Publishing a review article about the RLD
- Applying for a BLA instead of an ANDA
- Changing tablet color of the RLD
Correct Answer: Submitting a Paragraph IV certification in an ANDA
